Literature DB >> 1847020

Yohimbine increases sympathetic nerve activity and norepinephrine spillover in normal volunteers.

E Grossman1, R F Rea, A Hoffman, D S Goldstein.   

Abstract

It has been difficult to examine clinically the physiological role of central and peripheral alpha 2-adrenoceptors in humans. We simultaneously measured directly recorded peroneal skeletal muscle sympathoneural activity (MSNA) and the rate of appearance (spillover) of norepinephrine (NE) in forearm venous and arterial plasma before and at 15 min during intravenous administration of the alpha 2-blocker yohimbine (Yoh, 125 micrograms/kg bolus, 1 microgram.kg-1.min-1 infusion) in seven normal volunteers. Yoh administration increased mean arterial pressure by 16% (P less than 0.005), heart rate by 8% (P less than 0.05), and forearm vascular resistance by 67% (P less than 0.05). MSNA was increased by 73% (P less than 0.05), NE spillover into arterial blood by 125% (P less than 0.05), and forearm NE spillover (FSO) by 337% (P less than 0.005). Ganglion blockade by trimethaphan during Yoh infusion decreased MSNA to below detection limits and reversed Yoh-induced increases in arterial concentrations of NE and epinephrine. The results demonstrate that Yoh administration increases sympathoadrenal outflow. Because the mean increase of FSO was much larger than that of MSNA, the results suggest that alpha 2-adrenoceptors on sympathetic nerve endings modulate the neuronal release of NE for a given amount of sympathetic nerve traffic in humans; this effect seems prominent in the human limb.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1847020     DOI: 10.1152/ajpregu.1991.260.1.R142

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  26 in total

Review 1.  Neurocardiology: therapeutic implications for cardiovascular disease.

Authors:  David S Goldstein
Journal:  Cardiovasc Ther       Date:  2010-11-25       Impact factor: 3.023

2.  Cardiovascular reactivity to mental stress is not affected by alpha2-adrenoreceptor activation or inhibition.

Authors:  Christine Philippsen; Melanie Hahn; Lars Schwabe; Steffen Richter; Jürgen Drewe; Hartmut Schachinger
Journal:  Psychopharmacology (Berl)       Date:  2006-11-17       Impact factor: 4.530

3.  Synergistic effect of norepinephrine transporter blockade and α-2 antagonism on blood pressure in autonomic failure.

Authors:  Luis E Okamoto; Cyndya Shibao; Alfredo Gamboa; Leena Choi; André Diedrich; Satish R Raj; Bonnie K Black; David Robertson; Italo Biaggioni
Journal:  Hypertension       Date:  2012-02-06       Impact factor: 10.190

Review 4.  Genotype and vascular phenotype linked by catecholamine systems.

Authors:  David S Goldstein
Journal:  Circulation       Date:  2008-01-29       Impact factor: 29.690

Review 5.  Management of neurogenic orthostatic hypotension in patients with autonomic failure.

Authors:  Christoph Schroeder; Jens Jordan; Horacio Kaufmann
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

6.  Neuronal source of plasma dopamine.

Authors:  David S Goldstein; Courtney Holmes
Journal:  Clin Chem       Date:  2008-09-18       Impact factor: 8.327

Review 7.  Management of Supine Hypertension Complicating Neurogenic Orthostatic Hypotension.

Authors:  Jacquie Baker; Kurt Kimpinski
Journal:  CNS Drugs       Date:  2017-08       Impact factor: 5.749

Review 8.  The Pharmacology of Autonomic Failure: From Hypotension to Hypertension.

Authors:  Italo Biaggioni
Journal:  Pharmacol Rev       Date:  2017-01       Impact factor: 25.468

9.  Catecholamines 101.

Authors:  David S Goldstein
Journal:  Clin Auton Res       Date:  2010-07-11       Impact factor: 4.435

10.  Generalized and neurotransmitter-selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension.

Authors:  Yehonatan Sharabi; Richard Imrich; Courtney Holmes; Sandra Pechnik; David S Goldstein
Journal:  Mov Disord       Date:  2008-09-15       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.